Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Anti-CD19 CAR T-cells in B Cell Malignancies
NCT02546739Phase 1Unknown
- Sponsor
- Beijing DOING Biomedical Technology
- Start
- Mar 2021
- Primary completion
- Mar 2022
- Modality
- Gene Editing, Gene Silencing, CAR-T Cells
- Countries
- 1
01
Overview
Phase 1, open-label trial of Anti-CD19 CAR T-cells (Beijing Doing Biomedical) in acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL) and non-Hodgkin lymphoma (NHL) (3 cohorts), sponsored by Beijing DOING Biomedical Technology. Primary endpoint: Adverse events of each patient at 3 years. Status: unknown.
02
Drugs
Anti-CD19 CAR T-cells (Beijing Doing Biomedical)
03
Conditions
acute lymphoblastic leukemia (ALL)chronic lymphocytic leukemia (CLL)non-Hodgkin lymphoma (NHL)
Beyond the preview
Go deeper on NCT02546739.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02546739.